Form 4: Clearside Biomedical Director Anthony Gibney Acquires Stock Options

Director Anthony Gibney acquired stock options in Clearside Biomedical, Inc. on April 15, 2024.

Summary

• On April 15, 2024, Anthony S Gibney, a director of Clearside Biomedical, Inc., acquired stock options.
• The stock options grant the right to buy 45,000 shares of common stock at an exercise price of $1.29 per share.
• The options vest in 36 equal monthly installments starting April 30, 2024, contingent upon continuous service.
• The options expire on April 15, 2034.

Sentiment

Score: 7

Explanation: The granting of stock options to a director is generally a positive sign, indicating confidence in the company's future performance and aligning the director's interests with those of shareholders. However, it's a routine event.

Positives

• The acquisition of stock options by a director signals confidence in the company's future.

Future Outlook

NA

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule of 36 months is a typical vesting period for such grants.
• The exercise price is usually set at or above the market price at the time of the grant.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates